Literature DB >> 2344762

Pharmacokinetics of amikacin during continuous veno-venous hemofiltration.

E Armendariz1, L Chelluri, R Ptachcinski.   

Abstract

We studied the pharmacokinetics of amikacin in a patient with acute oliguric renal failure during continuous veno-venous hemofiltration (CVVH). The volume of distribution, terminal disposition rate constant and elimination half-life for amikacin were 27.9 L, 0.023.h-1 and 29.7 h, respectively. Total body clearance for amikacin was 10.54 ml/min and CVVH clearance was 10.11 ml/min. Sieving coefficient for amikacin was 0.93 +/- 0.16. Our data show that during CVVH at a filtration rate of 10 ml/min, the clearance of amikacin is similar to that reported in patients with renal failure who are not being treated with CVVH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344762     DOI: 10.1097/00003246-199006000-00023

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

1.  Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.

Authors:  Kevin S Akers; Jason M Cota; Christopher R Frei; Kevin K Chung; Katrin Mende; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 2.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

3.  Aminoglycoside use in renal failure.

Authors:  S Nayak-Rao
Journal:  Indian J Nephrol       Date:  2010-07

Review 4.  Critical care in uraemic children.

Authors:  J U Leititis; M Brandis
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

Review 5.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

Review 6.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.

Authors:  M Kihara; Y Ikeda; N Takagi; H Fujita; K Shibata; S Masumori; K Shiratori; S Umemura; H Shionoiri; M Ishii
Journal:  Intensive Care Med       Date:  1995-04       Impact factor: 17.440

Review 8.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 9.  A review of continuous renal replacement therapy.

Authors:  C G Flynn
Journal:  Ir J Med Sci       Date:  1994-07       Impact factor: 1.568

10.  An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.

Authors:  Deirdre M D'Arcy; Eoin Casey; Caitriona M Gowing; Maria B Donnelly; Owen I Corrigan
Journal:  BMC Pharmacol Toxicol       Date:  2012-11-08       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.